| About NicOx | |||
| Products | |||
| Naproxcinod NCX 6560 Full portfolio |
|||
| Maximizing portfolio | |||
| Co-development Research alliances Technology |
|||
| People | |||
| Board
of Directors Management Team Contacts Careers |
|||
| Investor & media | |||
| Press
releases Investor relations Fact file Financials Corporate governance "Informations Réglementées" Conferences |
|||
| Home | |||
| Directions
to NicOx Site en français |
|||
 |
NicOx fact file | ||
|
Listing Segment: |  Euronext Paris: Eurolist Next Economy |
|
|
|||
|
FTSE Classification | Economical group: non cyclical consumer goods (40) Industrial sector: pharmaceuticals (48) Industry sub-sector: pharmaceuticals (480) |
|
|
|||
|
Euroclear France code: | 7413 | |
|
Reuters code: | NCOX.PA | |
|
Bloomberg code: | COX.FP | |
|
IPO date: | November 3, 1999 | |
|
Gross proceeds: | 33 million euros | |
|
Follow-on offering: | May 21, 2001 | |
|
Gross proceeds: | 59 million euros | |
|
Private placement: | September 30, 2004 | |
|
Gross proceeds: | 26 million euros | |
|
Private placement: | April 28, 2006 | |
|
Gross proceeds: | approx. 45.5 million euros | |
| Rights issue : | February 16, 2007 | ||
| Net Proceeds : | 120.7 million euros | ||
|
Share price: | Euronext | |
| Share capital : | € 9 607 587.20 | ||
|
Number of outstanding shares: | 72,360,288 | |
|
Number of voting rights as of February 28, 2010: | 72,360,288 | |
|
Total number of voting right calculated on the basis of all the shares to which voting right are attached even if exercise thereof is suspended: |
72,360,288 | |
|
Public (as of 31.12.09): | 98.22% | |
| Analyst coverage : Search based in France / UK | |||
|
Shareholder structure: To its knowledge, as of 31 December 2009, NicOx' capital structure was: |
||
|
|||
|
Public: Main shareholders: |
98.22% |
|
| Founding managers: | 1.78% | ||
|
|||
|
|||
|
Contact: |
Karl HANKS Director of Investor Relations and Corporate Communications hanks@nicox.com |
|